starting with in vivo proof-of-concept testing to demonstrate the potential of its CT-02 molecular glues and CT-05 bifunctional degraders for autoimmune diseases, and more. As small molecules, CT ...

Kesmalea’s SELFTAC® platform is designed to solve the ‘size problem’ of large, bifunctional protein degraders by transforming them into small molecules SELFTAC drug candidates will combine ...